Project Grant R15CA271221

Award Date 4/1/23

Completion Date 3/31/27

Dollars Obligated $480K

Federal Agency

National Cancer Institute

Awardee

Albany College Of Pharmacy And Health Sciences (LCFLMPUNNGJ3)

Federal Grant Program

93.396

Assistance Type

Project Grant

Place of Performance

Albany, NY 12208, USA

Similar Awards

Project Grant R35CA305347
Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $1.056 million to the Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) to support research on overcoming resistance to targeted therapies in breast cancer. Initiated August 20, 2025, and extending through July 31, 2032, this project delivers fundamental and applied research aimed at understanding and addressing the development of drug resistance in...
Project Grant R01CA296285
Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $482,236 to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) on August 1, 2025, with a project completion date of July 31, 2030. This investigator-initiated Phase 2 clinical trial will evaluate the safety and efficacy of combining trastuzumab deruxtecan (T-DXD), an antibody-drug conjugate, with the anti-EGFR (epidermal growth factor receptor)...
Project Grant R21CA296504
Georgetown University received a $395,356 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective August 1, 2025, through July 31, 2027. The award supports fundamental research to elucidate the mechanisms of glucocorticoid receptor (GR) signaling in triple negative breast cancer (TNBC) progression, specifically investigating how a small population of "enabler" cells drive invasiveness and metastasis in the bulk tumor...
Project Grant R01CA292377
Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $627,371 project grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded on June 23, 2025, with an expected completion date of May 31, 2030. This award supports research focused on overcoming treatment resistance in estrogen receptor-positive (ER+) breast cancer through targeted degradation of cyclin-dependent kinases 4 and 6 (CDK4/6). The...
Project Grant R21CA307887
Federal Project Grant Award Summary Albert Einstein College of Medicine received a $431,970 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. The award supports research to decipher mechanisms of resistance to anti-TROP2 (tumor-associated glycoprotein 2) antibody-drug conjugates, specifically sacituzumab govitecan (SG), which is currently approved for treating advanced...
Project Grant R01CA295898
Federal Grant Award Summary The National Cancer Institute (NCI) awarded University of California, San Diego a $534,083 Project Grant effective June 3, 2025, under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on glucocorticoid signaling mechanisms induced by breast cancer cell-derived extracellular vesicles. The research project, scheduled for completion by May 31, 2030, will investigate how extracellular vesicles produced by breast cancer cells trigger...
Project Grant R21CA302968
GRANT AWARD SUMMARY Mayo Clinic received a $412,429 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to conduct research on novel therapeutic combinations for high-grade serous ovarian cancer (HGSOC). The award period extends from August 1, 2025, through July 31, 2027. The research focuses on developing and mechanistically evaluating drug-induced replication stress markers as therapeutic targets, specifically investigating the...
Project Grant R01CA299865
Federal Grant Award Summary The National Cancer Institute awarded a $730,398 Project Grant to Sloan-Kettering Institute for Cancer Research under the Cancer Treatment Research program (CFDA 93.395) beginning April 1, 2026, and extending through March 31, 2031. This award supports research investigating tumor regenerative cell (TRC) populations that drive resistance to neoadjuvant therapy and metastatic recurrence in locally advanced rectal cancer (LARC). The research deliverables include genomic...
Project Grant F32CA298459
Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $151,040 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective January 16, 2026, with completion targeted for July 31, 2028. This award supports a research training and development initiative focused on investigating the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion in triple negative breast cancer (TNBC). The project comprises two primary...
Cooperative Agreement U01CA296659
Federal Cooperative Agreement Award Summary The University of Colorado-Denver received a $625,470 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026, through April 30, 2031. This five-year project investigates novel dietary interventions targeting endocrine therapy-resistant (ETR) breast cancer through research on polyunsaturated fatty acids (PUFAs). Specifically, the research examines how n-3...

TARGETING SECRETED FACTORS IN ENDOCRINE RESISTANT BREAST CANCER THERAPY - ABSTRACT/SUMMARY: VARIOUS TYPES OF ENDOCRINE THERAPY HAVE BEEN USED FOR POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER. THESE THERAPIES ARE SAFE AND EFFECTIVE, BUT INITIALLY RESPONSIVE BREAST TUMORS OFTEN DEVELOP RESISTANCE AND EVENTUALLY RECUR. SINCE A COMMUNICATION BETWEEN TUMOR AND TUMOR CIRCUMSTANCE PLAYS AN IMPORTANT ROLE TO GROW TUMOR AND SPREAD TUMOR TO SECONDARY ORGANS, WE EXAMINED THE COMMUNICATION OF ENDOCRINE RESISTANT BREAST CANCER WITH STROMA WHICH IS THE PART OF A TISSUE OR ORGAN THAT HAS A CONNECTIVE AND STRUCTURAL ROLE IN CANCER. WE ESTABLISHED FOUR DIFFERENT ENDOCRINE RESISTANT BREAST CANCER CELL LINES AND EXAMINED THE COMMUNICATION OF THESE CELLS WITH FOUR STROMAL CELLS. WE FOUND THAT CCL5 AND ENDOGLIN MIGHT PLAY AN IMPORTANT ROLE IN ENDOCRINE RESISTANT BREAST CANCER. THUS, WE WILL 1) INVESTIGATE THE ROLE OF CCL5 AND ENDOGLIN IN THE CROSSTALK BETWEEN ERBC CELLS AND STROMAL CELLS, 2) UNVEIL THE MECHANISM OF THE UPREGULATED CCL5 AND ENDOGLIN IN CROSSTALK BETWEEN ERBC AND STROMA, AND 3) DEVELOP THERAPEUTIC STRATEGIES TO BLOCK THE PARACRINE INTERACTION BETWEEN THE STROMAL CELL AND ERBC CELL. WE WILL INVESTIGATE WHICH SECRETED FACTORS COULD SERVE AS A KEY REGULATOR IN THE TRANSITION OF BREAST CANCER CELLS TO ENDOCRINE RESISTANCE AND GAINING OF AN AGGRESSIVE PHENOTYPE. FURTHER, SECRETED FACTORS FROM THE COMMUNICATION BETWEEN ENDOCRINE RESISTANT BREAST CANCER AND STROMA MIGHT PROVE TO BE AN ATTRACTIVE TARGET FOR BREAST CANCER DRUGS. MOST OF THE CANCER DRUGS IN USE CURRENTLY HAVE BEEN DEVELOPED TO DIRECTLY IMPACT TUMOR CELLS. THESE DRUGS DO NOT DO MUCH TO BLOCK SIGNALS COMING FROM TUMOR CIRCUMSTANCE. OUR PROPOSED INVESTIGATION WILL GIVE US A SMALL LIST OF THE MOST POTENT OF THESE SIGNALS. DRUGS, SOME OF WHICH WE WILL IDENTIFY HERE, AND OTHERS THAT WILL HAVE TO BE DEVELOPED, THAT BLOCK THESE SIGNALS COULD LIMIT THE ABILITY OF THE TUMORS TO SPREAD TO SECONDARY ORGANS, WHICH SHOULD RESULT IN OVERALL SURVIVAL GAINS FOR PATIENTS.

Posted 3/27/23

Mod #	Description	ReasonForModification	Federal Obligation	Date
Not listed			$0	3/26/26
Not listed			$480.0k	3/27/23